RevImmune Inc specializes in T-Cell Technology & Development. The company's main product, IL-7, provides comprehensive T-cell support for Immunotherapies. RevImmune's platform technology is primarily focused on IL-7, which plays a crucial role in T cell development, expansion, proliferation, and mobilization. The company is also involved in the research and development of medicines for immune modulation, with a particular focus on treating lymphopenia-driven diseases. RevImmune offers drugs to treat these conditions and is currently developing CYT107 immune therapy for infectious diseases and cancer.